ADMA Biologics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by ADMA Biologics, Inc. on March 23, 2016. The report discloses the entry into a Material Definitive Agreement regarding the company's plasma supply operations.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a contractual agreement and does not contain financial performance data.
Material Changes
On March 23, 2016, the Company entered into an Amended and Restated Plasma Supply Agreement with Biotest Pharmaceuticals Corporation ("Biotest"). This agreement amends and restates the original Plasma Supply Agreement dated June 22, 2012. The primary change incorporates prior amendments and updates the terms to specifically accommodate the Company's additional plasma collection center.
Guidance, Outlook, and Risks
The filing does not contain management guidance, future outlook, or specific risk factors beyond the standard qualification that the description of the agreement is not complete. The full text of the agreement is referenced as Exhibit 10.10 to the Company's Annual Report on Form 10-K for the year ended December 31, 2016.
Key Facts for Investor Verification
- Verify the specific terms and pricing adjustments within the full text of the Amended and Restated Plasma Supply Agreement filed as Exhibit 10.10 to the 2016 Form 10-K.
- Confirm the operational status and capacity of the "additional plasma center" referenced in the new agreement.
- Review the historical performance of the relationship with Biotest Pharmaceuticals Corporation to assess the strategic importance of this supply agreement.